On Monday, Gilead Sciences, Inc (NASDAQ: GILD) opened lower -1.67% from the last session, before settling in for the closing price of $92.13. Price fluctuations for GILD have ranged from $62.07 to $98.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 4.16% over the last five years. Company’s average yearly earnings per share was noted -35.18% at the time writing. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.25 billion.
The firm has a total of 18000 workers. Let’s measure their productivity. In terms of profitability, gross margin is 77.98%, operating margin of 29.63%, and the pretax margin is 0.62%.
Gilead Sciences, Inc (GILD) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Gilead Sciences, Inc is 0.10%, while institutional ownership is 85.30%. The most recent insider transaction that took place on Nov 29 ’24, was worth 23,065,271. In this transaction Chief Financial Officer of this company sold 248,645 shares at a rate of $92.76, taking the stock ownership to the 138,919 shares. Before that another transaction happened on Nov 27 ’24, when Company’s Chief Medical Officer sold 164,211 for $91.92, making the entire transaction worth $15,094,013. This insider now owns 80,801 shares in total.
Gilead Sciences, Inc (GILD) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -35.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.50% during the next five years compared to 1.55% growth over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Check out the current performance indicators for Gilead Sciences, Inc (GILD). In the past quarter, the stock posted a quick ratio of 1.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.94. Likewise, its price to free cash flow for the trailing twelve months is 11.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.09, a number that is poised to hit 1.70 in the next quarter and is forecasted to reach 7.50 in one year’s time.
Technical Analysis of Gilead Sciences, Inc (GILD)
Analysing the last 5-days average volume posted by the [Gilead Sciences, Inc, GILD], we can find that recorded value of 7.79 million was better than the volume posted last year of 7.07 million. As of the previous 9 days, the stock’s Stochastic %D was 51.47%. Additionally, its Average True Range was 1.98.
During the past 100 days, Gilead Sciences, Inc’s (GILD) raw stochastic average was set at 70.45%, which indicates a significant increase from 54.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.92% in the past 14 days, which was lower than the 22.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $89.16, while its 200-day Moving Average is $76.12. Now, the first resistance to watch is $91.66. This is followed by the second major resistance level at $92.73. The third major resistance level sits at $93.31. If the price goes on to break the first support level at $90.01, it is likely to go to the next support level at $89.43. Should the price break the second support level, the third support level stands at $88.36.
Gilead Sciences, Inc (NASDAQ: GILD) Key Stats
There are currently 1,246,266K shares outstanding in the company with a market cap of 111.38 billion. Presently, the company’s annual sales total 27,116 M according to its annual income of 5,665 M. Last quarter, the company’s sales amounted to 7,545 M and its income totaled 1,253 M.
